Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole

被引:376
作者
Musher, DM
Aslam, S
Logan, N
Nallacheru, S
Bhaila, I
Borchert, F
Hamill, RJ
机构
[1] Michael E DeBakey VA Med Ctr, Med Serv, Infect Dis Sect, Houston, TX 77030 USA
[2] Baylor Coll Med, Dept Med, Houston, TX 77030 USA
[3] Baylor Coll Med, Dept Mol Virol & Microbiol, Houston, TX 77030 USA
[4] Aga Khan Univ, Karachi, Pakistan
关键词
D O I
10.1086/430311
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. Clostridium difficile is a frequent cause of serious nosocomial infection. Earlier reports have suggested that treatment with metronidazole cured nearly 90% of patients, with only a modest rate of recurrence of infection. In recent years, the rate of response to treatment with this drug has appeared to be much lower. Methods. We undertook a prospective, observational study of 207 patients who were treated with metronidazole for C. difficile colitis. Results. A total of 103 patients (50%) were cured by the initial course of therapy and had no recurrence of disease. Forty-six patients (22%) continued to have symptoms of colitis for >= 10 days despite treatment, and 58 (28%) responded initially but had a recurrence within the ensuing 90 days. The mortality rate among patients who developed C. difficile colitis was 27%, and it was higher among patients who did not respond fully to an initial course of therapy, compared with those who did (33% vs. 21%; P < .05) Conclusions. Because of the relatively poor response to therapy, additional approaches to prevention and/or treatment of C. difficile colitis appear to be warranted.
引用
收藏
页码:1586 / 1590
页数:5
相关论文
共 33 条
  • [1] Clostridium difficile vaccine and serum immunoglobulin G antibody response to toxin A
    Aboudola, S
    Kotloff, KL
    Kyne, L
    Warny, M
    Kelly, EC
    Sougioultzis, S
    Giannasca, PJ
    Monath, TP
    Kelly, CP
    [J]. INFECTION AND IMMUNITY, 2003, 71 (03) : 1608 - 1610
  • [2] Secular trends in hospital-acquired Clostridium difficile disease in the United States, 1987-2001
    Archibald, LK
    Banerjee, SN
    Jarvis, WR
    [J]. JOURNAL OF INFECTIOUS DISEASES, 2004, 189 (09) : 1585 - 1589
  • [3] Antibiotic-associated diarrhea
    Bartlett, JG
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (05) : 334 - 339
  • [4] BARTLETT JG, 1984, REV INFECT DIS, V6, P235
  • [5] Fekety R, 1997, AM J GASTROENTEROL, V92, P739
  • [6] Recurrent Clostridium difficile diarrhea: Characteristics of and risk factors for patients enrolled in a prospective, randomized, double-blinded trial
    Fekety, R
    McFarland, LV
    Surawicz, CM
    Greenberg, RN
    Elmer, GW
    Mulligan, ME
    [J]. CLINICAL INFECTIOUS DISEASES, 1997, 24 (03) : 324 - 333
  • [7] Outbreak of Clostridium difficile infection in a long-term care facility:: Association with gatifloxacin use
    Gaynes, R
    Rimland, D
    Killum, E
    Lowery, HK
    Johnson, TM
    Killgore, G
    Tenover, FC
    [J]. CLINICAL INFECTIOUS DISEASES, 2004, 38 (05) : 640 - 645
  • [8] Clindamycin, cephalosporins, fluoroquinolones, and Clostridium difficile-associated diarrhea:: This is an antimicrobial resistance problem
    Gerding, DN
    [J]. CLINICAL INFECTIOUS DISEASES, 2004, 38 (05) : 646 - 648
  • [9] Giannasca PJ, 2004, VACCINE, V22, P848, DOI 10.1016/j.vaccine.2003.11.030
  • [10] Clostridium difficile -: Associated diarrhea
    Johnson, S
    Gerding, DN
    [J]. CLINICAL INFECTIOUS DISEASES, 1998, 26 (05) : 1027 - 1034